v3.26.3
STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2026
STOCKHOLDERS' EQUITY  
Schedule of designation, shares authorized, and shares outstanding for the Company's Preferred Stock

​

​

​

​

​

​

​

​

​

​

​

​

​

Preferred Shares

​

Preferred Shares

​

Potentially Issuable

Preferred Stock Series Designation

  ​ ​ ​

Authorized

  ​ ​ ​

Outstanding

  ​ ​ ​

Preferred Shares

Series Seed

​

​

213,000,000

​

​

204,772,940

​

​

8,227,060

Series A

​

​

207,000,000

​

​

185,440,880

​

​

21,559,120

Series T

​

​

99,000,000

​

​

9,642,080

​

​

89,357,920

Schedule of inputs valued under using the Black-Scholes pricing model

​

​

​

​

​

​

​

​

  ​ ​ ​

2026

  ​ ​ ​

2025

 

Expected life (years)

 

6.5

 

6.5

​

Risk-free interest rate

 

3.95 - 5.19

%  

0.6 - 4.6

%

Expected volatility

 

54.6 - 56.2

%  

37.0 - 52.9

%

Annual dividend yield

 

0

%  

0

%

Schedule of stock option activity and related information

​

​

​

​

​

​

​

​

​

​

​

​

​

Options

  ​ ​

​

Weighted- Average Exercise Price

  ​ ​

​

Aggregate Intrinsic Value

Outstanding at December 31, 2025

​

​

158,828,223

​

$

0.59

​

$

-

Granted

​

​

13,660,000

​

​

1.61

​

​

-

Exercised

​

​

(134,910)

​

​

0.21

​

​

188,130

Forfeited

​

​

(4,606,346)

​

​

1.28

​

​

-

Expired

​

​

-

​

​

-

​

​

-

Outstanding at September 30, 2026

​

​

167,746,967

​

$

0.65

​

$

154,859,604

Exercisable at September 30, 2026

​

​

129,795,680

​

$

0.48

​

$

145,384,075

Schedule of stock option expense

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30, 

​

Nine Months Ended September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

 

2026

  ​ ​ ​

2025

Cost of revenues

​

$

453,351

​

$

104,159

​

$

1,257,208

​

$

691,556

General and administrative

​

 

517,980

​

 

418,594

​

 

1,558,258

​

 

1,399,554

Sales and marketing

​

 

934,661

​

 

520,837

​

 

3,233,265

​

 

3,204,876

Vinovest

​

​

1,749

​

​

—

​

​

1,749

​

​

—

Research and development

​

 

518,243

​

 

208,828

​

 

1,552,964

​

 

1,133,950

Total

​

$

2,425,984

​

$

1,252,418

​

$

7,603,444

​

$

6,429,936